Article Text

SAT0358 Efficacy of Methotrexate in Giant Cell Arteritis
  1. M.J. Koster1,
  2. C. Crowson2,
  3. C. Labarca3,
  4. F. Muratore4,
  5. K.J. Warrington1
  1. 1Rheumatology
  2. 2Health Sciences Research, Mayo Clinic, Rochester, United States
  3. 3Rheumatology, Clinica Alemana de Santiago, Santiago, Chile
  4. 4Rheumatology, Azienda Ospedaliera Arcispedale Santa Maria NuovaIRCCS, Reggio Emilia, Italy


Background Prospective trials evaluating methotrexate (MTX) as adjunct immunosuppression in Giant cell arteritis (GCA) have provided evidence of a modest benefit for reducing risk of relapse and decreasing glucocorticoid exposure. Limited information is available regarding the use of this medication in routine clinical practice.

Objectives To determine the effect of methotrexate on relapse risk and glucocorticoid use in a large single-institution cohort of patients with GCA.

Methods A retrospective review of patients diagnosed with GCA from 1998–2013 was performed. Patients diagnosed with GCA were ≥50 years and had either a temporal artery biopsy (TAB) that was consistent with GCA or radiographic evidence of large vessel vasculitis. Each patient with GCA treated with adjunct MTX (case) was matched to a similar GCA patient without MTX (control). Cases and controls were matched on age, sex, disease duration at start of MTX and initial corticosteroid dose. Each control was assigned an index date to make the number of days from GCA diagnosis to index date in the control equivalent to the number of days from the GCA diagnosis to the start of MTX in cases. Baseline demographics, disease characteristics and relapse events were abstracted. Glucocorticoid requirements and relapse events before and after methotrexate initiation (or corresponding index date) were compared using rate ratios.

Results A total of 84 patients with GCA receiving MTX were identified and compared to 84 patients with GCA receiving only prednisone. Mean age at diagnosis 69.5±7.0 years in cases and 70.3±6.9 in controls. No significant differences in demographics, laboratory parameters or baseline disease characteristics were observed between groups. Mean initial prednisone doses were similar (53.5±15.8 mg/day in cases, 55.0±13.5 mg/day in controls). The median (interquartile range [IQR]) time from GCA diagnosis to MTX initiation in cases was 0.7 (0.3, 1.6) years and the median (IQR) starting dose was 13.5 (10, 15) mg per week.

Prior to MTX initiation the observed relapse rate was 11.8 relapses per 10 person-years and decreased to 3.69 relapses per 10-person years following initiation. The rate ratio comparing relapse rates observed after MTX to the rate prior to initiation was significantly reduced; rate ratio (95% CI): 0.31 (0.24, 0.41). In the control group the relapse rate was 3.42 relapses per 10 person-years before the index date and 2.27 relapses per 10 person-years following the index date [rate ratio (95% CI); 0.66 (0.45, 0.99). Although both groups had a reduction in relapse rate ratios, the rate of decrease in relapse rate was significantly greater in patients on MTX than those not on MTX (p=0.002) [figure]. The ratio of rates after MTX initiation/index date for achieving steroid doses <10 mg/day for >6 months or steroid discontinuation >6 months did not differ for cases and controls.

Conclusions In this large single-institution cohort, the addition of methotrexate to glucocorticoid decreased the rate of subsequent relapse by 2-fold compared to patients on glucocorticoids alone. Methotrexate should be considered as adjunct therapy in patients with relapsing GCA to decrease the risk of further relapse events.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.